Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRDMOs), has announced its plans to recruit over 500 scientists during the year 2021.
As the first phase of this drive, the company has initiated recruitment for scientific talent in API process and analytical research & development, particle engineering and sciences, niche platform technologies as well as life cycle management, the company said in a statement.
Commenting on the development, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, “Over the past 18-24 months we have been significantly augmenting our R&D facilities and rapidly growing our customer outreach. We expect these efforts to bear fruit in the coming months and are therefore looking to expand our team. This addition to our high-quality talent pool will help us better serve our customers by accelerating their projects involving complex chemistry and next generation technologies.”
The company announced Sai Nxt, an organisation-wide initiative aimed at transforming itself into a new generation CRO/CDMO. Guided by the insights and feedback from its customers, it committed to investing over US$150M between 2019 and 2023 to significantly expand and upgrade its R&D and manufacturing facilities, deepen scientific & technological capabilities, strengthen automation and data systems.
As part of Sai Nxt, the company has added 172 KL API & Intermediate manufacturing capacity, opened a discovery biology Lab in Cambridge, Massachusetts, USA, a centre of excellence in process R&D in Manchester, UK and an 83,000 sq. ft. integrated research & technology facility in Hyderabad with technology platforms including flow chemistry, biocatalysis and crystallization.
Sai Life Sciences works with innovator pharma and biotech companies globally, accelerating the discovery, development and manufacture of complex small molecules. As a pure-play CRO-CDMO, Sai Life Sciences has served a diverse set of NCE development programs, consistently delivering value based on its quality and responsiveness. Sai Life Sciences is backed by global investors, TPG Capital and HBM Healthcare Investments.
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.